Obesity in female life--from molecular to clinical aspects.
Obesity gains increasing prevalence world-wide. Multifactorially caused it presents itself in numerous heterogeneous phenotypes with a wide spectrum of clinical symptoms. The full-blown female obesity syndrome is initiated already in childhood, associated with ovarian hyperandrogenaemia (polycystic ovary syndrome) in the reproductive phase, and characterised by increasing co-morbidity (cancer; metabolic syndrome; arteriosclerosis) in the postmenopausal state leading to shortened longevity. Due to the complexity of psychic, somatic and endocrine-metabolic disturbances a causal break-through in the treatment of the disease could not be achieved yet, but the enhanced basal understanding and recently investigated pharmaceutical principles might enable to improve the therapeutical approaches.
Geisthövel
F
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D015870:Gene Expression / Q000502:physiology; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D020738:Leptin; D008875:Middle Aged; D009369:Neoplasms / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D009765:Obesity / Q000150:complications / Q000503:physiopathology* / Q000628:therapy; D011085:Polycystic Ovary Syndrome / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D011247:Pregnancy; D011506:Proteins / Q000235:genetics* / Q000502:physiology; D012307:Risk Factors
D020738:Leptin; D011506:Proteins